The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• RAS oncoproteins have historically been challenging therapeutic targets in cancer.
• Recent breakthroughs have enabled the development of diverse RAS inhibitors.
• Several RAS inhibitors are now approved or in clinical trials for RAS-mutant cancers.

Purpose of the Study:

• To review current classes of RAS inhibitors, focusing on those in clinical development.
• To discuss factors influencing response to RAS inhibition, including tumor context and resistance.
• To provide an outlook on future therapeutic strategies for RAS-mutant cancers.

Main Methods:

• Review of current literature on RAS inhibitors.
• Discussion of clinical trial data for allele-specific KRAS, panKRAS, and panRAS inhibitors.
• Analysis of determinants of response and resistance mechanisms.

Main Results:

• Multiple classes of RAS inhibitors, including allele-specific KRAS, panKRAS, and panRAS inhibitors, are under clinical evaluation.
• Factors such as tumor context and resistance mechanisms influence patient response.
• Approved RAS inhibitors offer improved therapeutic options for specific RAS-mutant cancers.

Conclusions:

• The development of RAS inhibitors marks a significant advancement in treating RAS-mutant cancers.
• Combination therapies are anticipated to be crucial for future RAS-targeting strategies.
• Continued research is essential to overcome resistance and optimize treatment outcomes.